

Massive myocardial infiltration by primary anaplastic T-cell lymphoma: a case report

Luca Cumitini ^{1,2}, Lidia Rossi², Ailia Giubertoni², and Giuseppe Patti ^{1,2*}

¹Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; and ²Department of Thoracic and Cardiovascular Diseases, Maggiore della Carità Hospital, Via Mazzini 18, 28100 Novara, Italy

Received 8 September 2022; first decision 6 January 2023; accepted 4 May 2023; online publish-ahead-of-print 9 May 2023

Background

Myocardial infiltration by primary cardiac neoplasm is a rare entity, providing diagnostic and therapeutic challenges. The pathological spectrum includes more frequently benign forms. Refractory heart failure, pericardial effusion, and arrhythmias due to infiltrative mass are the most common clinical manifestations.

Case summary

We describe the case of a 35-year-old man complaining of shortness of breath and weight loss in the last 2 months. A previous acute myeloid leukaemia treated with allogenic bone marrow transplant was reported. Transthoracic echocardiography revealed an apical thrombus in the left ventricle, with inferior and septal hypokinesia conditioning a mildly reduced ejection fraction, circumferential pericardial effusion, and abnormal right ventricular thickening. Cardiac magnetic resonance confirmed diffuse thickening of the right ventricular free wall due to myocardial infiltration. Positron emission tomography showed the presence of neoplastic tissue with increased metabolic activity. A pericardiectomy was performed showing a widespread cardiac neoplastic infiltration. Histopathological analysis done on right ventricular pathological samples obtained during cardiac surgery revealed the presence of a rare and aggressive cardiac anaplastic T-cell non-Hodgkin lymphoma. Few days after the operation, the patient developed refractory cardiogenic shock and unluckily died before initiating an adequate antineoplastic therapy.

Discussion

Primary cardiac lymphoma is not frequent, and the lack of specific symptoms makes the diagnosis extremely challenging and often limited to autopsy findings. Our case highlights the importance of an appropriate diagnostic algorithm, requiring non-invasive multi-modality assessment imaging and then invasive cardiac biopsy. This approach may allow an early diagnosis and an adequate therapy for this otherwise fatal pathology.

Keywords

Myocardial infiltration • Primary cardiac lymphoma • Cardiac magnetic resonance • Echocardiography • Non-Hodgkin lymphoma • Case report

ESC Curriculum

6.8 Cardiac tumours • 2.1 Imaging modalities • 2.4 Cardiac computed tomography • 2.3 Cardiac magnetic resonance • 2.2 Echocardiography

* Corresponding author. Tel: +39 0321 3733597, Email: giuseppe.patti@uniupo.it

Handling Editor: Suzan Hatipoglu

Peer-reviewers: Ojas Mehta; Livia Gheorghie

Compliance Editor: Emmanouil Mantzouranis

Supplementary Material Editor: Raffaella Siang

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Learning points

- Primary cardiac lymphomas are rapidly growing tumours that involve predominantly the right side of the heart.
- Extranodal lymphomas are increasingly seen with acquired immunodeficiencies such as HIV infection or after bone marrow and solid organ transplantation.
- Exceptional diagnostic and therapeutic challenges were provided due to the rarity of this tumour.
- Multimodality imaging is essential to determine the characteristics of a cardiac neoplasm.
- Non-specific signs and symptoms, late diagnosis, and rapid evolution of cardiac involvement are the major factors affecting the outcome.
- Overall prognosis is poor, and treatment options are limited.

Introduction

Primary cardiac neoplasm is a rare entity. The pathological spectrum includes more frequently benign forms, with cardiac myxoma being the most prevalent one. Regarding malignant tumours, primary cardiac lymphoma (PCL) accounts for <2% of cardiac neoplasms.¹ Primary cardiac lymphoma is a subtype of non-Hodgkin B cell lymphoma. Given the lack of specific symptoms, the diagnosis of PCL may be challenging. Refractory heart failure, pericardial effusion, and arrhythmias due to infiltrative mass are the most common clinical features.² A multimodality imaging, with echocardiography, computed tomography (CT), and cardiac magnetic resonance imaging (MRI), is crucial to determine the characteristics of a cardiac tumour and can guide towards the diagnosis of PCL. This report presents an interesting case of a rare and aggressive anaplastic T-cell non-Hodgkin lymphoma involving mainly the right side of the heart.

Timeline

Two years prior to admission	An acute myeloid leukaemia treated with allogeneic bone marrow transplant was reported.
Six months prior to admission	Leukaemia relapse treated with chemotherapy and in pathological complete remission at hospital admission.
Day 1	Hospital admission for shortness of breath and weight loss.
Day 2	An abnormal right ventricular thickening was revealed by echocardiography.
Day 6	Myocardial infiltration of the right ventricular free wall was suspected by cardiac magnetic resonance imaging.
Day 8	At chest computed tomography scan, the right coronary artery appeared to be incorporated by the pathological tissue.
Day 10	Cardiac positron emission tomography showed the presence of neoplastic tissue with increased metabolic activity.
Day 11	A percutaneous endomyocardial biopsy obtained during cardiac catheterization was inconclusive.
Day 13	The patient's haemodynamic status rapidly worsened.
Day 15	A pericardiectomy was performed, taking in pathological samples for histopathological analysis.
Day 26	Histopathological analysis on right ventricular pathological samples taken during surgery revealed

Continued

tissue involvement by a cardiac anaplastic large T-cell non-Hodgkin lymphoma.

Day 27

The patient developed a refractory cardiogenic shock and died before initiating an adequate antineoplastic therapy.

Case presentation

A 35-year-old man without cardiovascular risk factors presented in the Emergency Department complaining of shortness of breath and weight loss in the last 2 months. A previous history of acute myeloid leukaemia treated with allogeneic bone marrow transplant and subsequent relapse treated with chemotherapy was reported. Pathological complete remission with azacitidine and venetoclax was described, and disease-free survival was reported at the latest follow-up 4 months before. Upon admission, body temperature was 37.1°C, heart rate was 87 beats per minute, saturation on room air oxygen was 98%, and blood pressure was 130/80 mmHg. Physical examination showed normal heart sounds, without murmur, and bilateral lower extremities pitting oedema. Q-waves in inferior leads, diffuse T-waves inversion, and low QRS voltage were present at electrocardiography (*Figure 1*). Blood tests revealed leucocytopenia (2900/μL, with normal value 4500–11 000/μL), normal renal, and liver function. Blast cells were not detected on peripheral blood smear. Transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) demonstrated inferior and septal hypokinesia conditioning a mildly reduced left ventricular ejection fraction (45%), circumferential pericardial effusion without cardiac tamponade, and abnormal right ventricular thickening (*Figure 2*, in-line video, and see [Supplementary material online, Video S1](#)). Furthermore, an apical thrombus in the left ventricle was present (*Figure 3*, in-line video, and see [Supplementary material online, Video S2](#)). Echocardiographic parameters of longitudinal function of the right ventricle were normal. The patient was admitted to the coronary care unit, and anticoagulation therapy with low-molecular-weight heparin was started, with evidence of thrombus resolution in approximately 10 days. Cardiac MRI confirmed a diffuse thickening of the right ventricular free wall (maximum diameter 30 mm). The tissue was iso-intense on T1-weighted images, without late gadolinium enhancement (LGE), suggestive for myocardial infiltration primarily of the right ventricle, extending to the right atrium and left ventricle. A subendocardial LGE of left ventricular inferior wall was also observed, with ischemic distribution (*Figure 4*, in-line video, and see [Supplementary material online, Video S3](#)). An elevation of high-sensitivity troponin I values was documented, and coronary angiography was performed indicating no atherosclerotic coronary artery disease. However, at chest CT scan, the right coronary artery appeared to be incorporated by the pathological tissue (see [Supplementary material online, Video S4](#)). Positron emission tomography showed the presence of neoplastic tissue with




Figure 1 Q-waves in inferior leads, diffuse T-waves inversion, and low QRS voltage were revealed by 12-lead electrocardiography.




Figure 2 Transthoracic at apical four-chamber view (A) and transoesophageal at mid-oesophageal four-chamber view 0-degrees (B) echocardiogram showed abnormal right ventricular thickening (arrows).

increased metabolic activity within the heart, in ascending aorta and aortic arch (Figure 5). No neoplastic localization was found at bone marrow biopsy. During hospitalization, patient's haemodynamic status rapidly worsened in few days. A sustained ventricular tachycardia occurred

and was successfully treated with intravenous amiodarone and metoprolol. Subsequent TTE and TOE revealed severe impairment of the right ventricular function and dilatation of the inferior vena cava (see [Supplementary material online, Video S5](#)). Since percutaneous




Figure 3 Transthoracic two-dimensional (A) and three-dimensional (B) echocardiography showed an apical thrombus in the left ventricle (arrows).




Figure 4 Cardiac magnetic resonance imaging confirmed thickening of the right ventricular free wall due to myocardial infiltration (arrows) in short-axis view (A) and four-chamber view (B).

endomyocardial biopsy obtained during cardiac catheterization was inconclusive, a surgical pericardiectomy was performed via median sternotomy; it showed widespread cardiac neoplastic infiltration. Histopathological analysis on right ventricular pathological samples taken during surgery demonstrated tissue involvement by a rare and aggressive cardiac anaplastic large T-cell non-Hodgkin lymphoma (BCL2+, CD4+, CD30+, ALK–, and Ki-67 90%). The atypical lymphoid cells were large-sized with abundant cytoplasm, growing in a cohesive pattern (see [Supplementary material online, Figure S6](#)). Few days after surgery, the patient developed refractory cardiogenic shock treated with dobutamine and norepinephrine. He unluckily passed away in 1 day, before initiating an adequate antineoplastic therapy.

Discussion

Cardiac masses arising from the heart are potentially lethal, and almost 75% of them are benign. Metastatic deposits represent the lion's share of cardiac malignancies, whereas the most common primary malignant tumours are lymphomas and sarcomas.³ Approximately 80% of cases of primary cardiac lymphoma in immunocompetent hosts are represented by diffuse B-cell lymphoma, whereas in patients with immunodeficiency states, such as those with HIV infection or after bone marrow and solid organ transplantation, small non-cleaved or immunoblastic lymphomas are more frequent.⁴ Cardiac lymphomas generally




Figure 5 Cardiac positron emission tomography showed a neoplastic tissue with increased metabolic activity (A, B and D, arrows). Similar characteristics were also evident in ascending aorta and aortic arch (C and E, arrows).

involve the right side of the heart, but may also involve valves, ascending aorta or pulmonary artery, often presenting as a nodular or polypoid mass with variable myocardial infiltration.⁵ Indicators of malignancy are pericardial effusion, sometimes complicated with cardiac tamponade, irregular lesion borders of the mass, and lymphomatous myocardial infiltration. Although rare, cardiac conduction disturbances may be the first manifestation of cardiac lymphoma or of its treatment failure.⁶ T-cell lymphomas are more likely to spread widely, with pericardial effusion being more closely linked to the expansion of the disease.⁷ Ventricular thrombosis is generally due to malignancy-related hypercoagulability. The common presentation is a mass in one or multiple chambers of the heart, whereas an isolated lymphomatous infiltration of the myocardium is more rarely observed.⁸ As reported in the latest European Society of Cardiology (ESC) guidelines on cardio-oncology,⁹ a multimodality imaging is important to assess the characteristics of a cardiac tumour. Echocardiography usually represents the first imaging step, while cardiac CT scan and MRI offer further tissue characterization and anatomical information. Unlike other malignant tumours, such as sarcomas, lymphomas generally lack regions of central necrosis and haemorrhage. As a result, at cardiac MRI sequences, lymphomas are typically homogeneous and isointense on T1- and T2-weighted images. Similarly, unlike other malignant tumours, there is generally minimal contrast agent uptake.¹⁰ Of note, nuclear imaging is useful for the therapeutic management and to evaluate the response to chemotherapy.¹¹ Biopsy and histopathological evaluation are required to confirm the diagnosis if a primary tumour is suspected, and/or diagnosis is uncertain at imaging.⁹⁻¹² In our case, percutaneous endomyocardial biopsy was inconclusive, then a surgical pericardiectomy was performed and provided samples for histopathological analysis. In selected cases, cytological examination of pericardial fluid may help to reach a diagnosis by detection monoclonal lymphocytes at flow cytometry analysis. In our patient, the diagnosis of PCL was based on REAL (Revised European American Lymphoma) classification.¹³ The most frequent differential diagnosis facing a cardiac mass includes intracardiac thrombus, which usually arises in the left ventricle in the setting of hypokinetic-dilated cardiomyopathy, and a benign mesenchymal tumour, mostly myxoma, attached to the endocardial surface by a stalk and possibly associated with emboli-related symptoms.¹⁴ With regard to treatment, chemotherapy has shown to have the greatest effect on survival in patients

with lymphoma,¹ while surgical removal of the mass is generally not indicated. However, because of the rarity of the disease, robust data are lacking. Overall, prognosis is poor, with a median survival <1 year after the diagnosis.

In conclusion, this case highlights the importance of an appropriate diagnostic algorithm, requiring a non-invasive, multimodality assessment imaging and then invasive cardiac biopsy.⁹ This approach may allow an early diagnosis and an adequate therapy of this otherwise fatal pathology. Non-specific signs and symptoms, late diagnosis, and rapid evolution of cardiac involvement are the major factors affecting outcome.

Lead author biography



Luca Cumitini was born in Turin, Italy, in 1993. He graduated as a medical doctor in School of Medicine of Turin University in 2019. He is currently a cardiology resident in the Department of Thoracic and Cardiovascular Diseases of University of Eastern Piedmont, Novara, Italy. He has a special interest for heart failure and intensive cardiac care.

Supplementary material

Supplementary material is available at *European Heart Journal – Case Reports*.

Acknowledgements

The authors are grateful to cardiologists who worked to provide high-quality care to the patient. We would also like to thank our haematologists, cardiac surgeons, and pathologists for their collaboration to the multidisciplinary case management.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as [Supplementary data](#).

Consent: The authors confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: None declared.

Funding: None to declare.

Data availability

The data underlying this article are available in the article and in its online supplementary material.

References

- Petrich A, Cho SI, Billett H. Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns. *Cancer* 2011;**117**:581–589.
- Ikeda H, Nakamura S, Nishimaki H, Masuda K, Takeo T, Kasai K, et al. Primary lymphoma of the heart: case report and literature review. *Pathol Int* 2004;**54**:187–195.
- Grebenc ML, Rosado de Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: radiologic–pathologic correlation. *Radiographics* 2000;**20**:1073–1103.
- Re A, Cattaneo C, Rossi G. HIV and lymphoma: from epidemiology to clinical management. *Mediterr J Hematol Infect Dis* 2019;**11**:e2019004.
- Rerkpattanapit P, Wongpraparut N, Jacobs L, Kotler M. Cardiac manifestations of acquired immunodeficiency syndrome. *Arch Intern Med* 2000;**160**:602–608.
- Monsuez JJ, Frija J, Hertz-Pannier L, Miclea JM, Extra JM, Boiron M. Non-Hodgkin's lymphoma with cardiac presentation: evaluation and follow-up with echocardiography and MR imaging. *Eur Heart J* 1991;**12**:464–467.
- Zhao Y, Huang S, Ma C, Zhu H, Bo J. Clinical features of cardiac lymphoma: an analysis of 37 cases. *J Int Med Res* 2021;**49**:300060521999558.
- Chen H, Qian S, Shi P, Liu L, Yang F. A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019. *Int J Hematol* 2020;**112**:65–73.
- Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J* 2022;**43**:1–133.
- Scheggi V, Mazzoni C, Mariani T, Stefano PL. Left-sided primary cardiac lymphoma: a case report. *Egypt J Intern Med* 2020;**32**:27.
- Johri A, Baetz T, Isotalo PA, Nolan RL, Sanfilippo AJ, Ropchan G. Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome. *Can H Cardiol* 2009;**25**:e210-212.
- Motwani M, Kidambi A, Herzog BA, Uddin A, Greenwood JP, Plein S. MR imaging of cardiac tumors and masses: a review of methods and clinical applications. *Radiology* 2013;**268**:26–43.
- Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;**84**:1361–1392.
- Carras S, Berger F, Chalabreysse L, Callet-Bauchut E, Cordier JF, Salles G, et al. Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. *Hematol Oncol* 2016;**35**:510–519.